184 related articles for article (PubMed ID: 37691397)
21. [Periocular Merkel Cell Carcinoma - an overview of clinical aspects and current therapeutic options].
Esser E; Grünewald I; Mihailovic N
Laryngorhinootologie; 2024 Jun; 103(6):404-412. PubMed ID: 38128577
[TBL] [Abstract][Full Text] [Related]
22. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker A; Burgess MA; Hanks BA; Olencki T; Kendra K; Church C; Akaike T; Ramchurren N; Shinohara MM; Salim B; Taube JM; Jensen E; Kalabis M; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879601
[TBL] [Abstract][Full Text] [Related]
23. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
24. Landscape of current and future therapies of Merkel cell carcinoma.
Kwiatkowska D; Reich A
Dermatol Ther; 2020 May; 33(3):e13281. PubMed ID: 32083780
[TBL] [Abstract][Full Text] [Related]
25. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in Merkel cell carcinoma.
Robinson CG; Tan D; Yu SS
F1000Res; 2019; 8():. PubMed ID: 31824653
[TBL] [Abstract][Full Text] [Related]
27. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
28. [Merkel-cell carcinoma].
Moll I
Pathologe; 2019 Dec; 40(Suppl 3):350-354. PubMed ID: 31820040
[TBL] [Abstract][Full Text] [Related]
29. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
[TBL] [Abstract][Full Text] [Related]
30. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for Merkel cell carcinoma.
Angeles CV; Sabel MS
J Surg Oncol; 2021 Mar; 123(3):775-781. PubMed ID: 33595894
[TBL] [Abstract][Full Text] [Related]
32. Merkel Cell Carcinoma in the HIV-1/AIDS Patient.
Goldstein RH; DeCaprio JA
Cancer Treat Res; 2019; 177():211-229. PubMed ID: 30523626
[TBL] [Abstract][Full Text] [Related]
33. How we treat Merkel cell carcinoma: within and beyond current guidelines.
Park SY; Doolittle-Amieva C; Moshiri Y; Akaike T; Parvathaneni U; Bhatia S; Zaba LC; Nghiem P
Future Oncol; 2021 Apr; 17(11):1363-1377. PubMed ID: 33511866
[TBL] [Abstract][Full Text] [Related]
34. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
[TBL] [Abstract][Full Text] [Related]
35. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
36. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
37. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
[TBL] [Abstract][Full Text] [Related]
38. Immune activity in Merkel cell carcinoma.
Nakamura M; Morita A
J Dermatol; 2022 Jan; 49(1):68-74. PubMed ID: 34766373
[TBL] [Abstract][Full Text] [Related]
39. Molecular and immune targets for Merkel cell carcinoma therapy and prevention.
Cohen L; Tsai KY
Mol Carcinog; 2019 Sep; 58(9):1602-1611. PubMed ID: 31116890
[TBL] [Abstract][Full Text] [Related]
40. The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.
Kok DL; Wang A; Xu W; Chua MST; Guminski A; Veness M; Howle J; Tothill R; Kichendasse G; Poulsen M; Sandhu S; Fogarty G
Asia Pac J Clin Oncol; 2020 Dec; 16(6):312-319. PubMed ID: 32757453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
